
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastric Cancer
Key Takeaways
- FDA priority review targets CLDN18.2-positive (≥25% tumor cells) advanced gastric/GEJ/esophageal adenocarcinoma after progression, positioning AZD0901 as a potential biomarker-selected alternative to standard chemotherapy.
- CLARITY-Gastric01 (global, randomized, open-label, sponsor-blinded) selected 2.2 mg/kg Q3W after a dose-finding stage and compared against line-appropriate regimens including ramucirumab/paclitaxel and irinotecan.
The FDA accepted a BLA with priority review for sonesitatug vedotin in previously treated CLDN18.2-positive gastric/GEJ cancer based on OS data from CLARITY-Gastric01.
The FDA has accepted and granted priority review to a biologics license application (BLA) for sonesitatug vedotin (Sone-Ve; AZD0901), a CLDN18.2-directed antibody-drug conjugate (ADC), for the second- or later-line treatment of locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or esophageal adenocarcinoma with CLDN18.2 expression on at least 25% of tumor cells at any staining intensity.1 A Prescription Drug User Fee Act target action date is expected in the second quarter of 2027.
The application is based on the phase 3 CLARITY-Gastric01 trial (NCT06346392), in which sonesitatug vedotin improved overall survival (OS) vs investigator’s choice of therapy in the intention-to-treat population (median, 10.6 vs 6.4 months; HR, 0.58; 95% CI, 0.47-0.73; P = .000004).1,2 The data were presented at
“Sone-Ve is the first CLDN18.2-targeted antibody drug conjugate to demonstrate an [OS] benefit in this setting,” said Rui-Hua Xu, MD, PhD, of the Department of Medical Oncology at Sun Yat-sen University Cancer Center in Guangzhou, China, and principal investigator of CLARITY-Gastric01, in a news release.1
CLARITY-Gastric01 Trial Design
CLARITY-Gastric01 is a randomized, open-label, sponsor-blinded, global phase 3 trial conducted at 175 centers in 19 countries. In stage 1, patients were randomly assigned 1:1:1 to sonesitatug vedotin 2.2 mg/kg or 1.8 mg/kg every 3 weeks or to investigator’s choice for dose selection; stage 2 continued with the 2.2 mg/kg dose.1 Of 594 patients enrolled, 267 received sonesitatug vedotin 2.2 mg/kg and 265 received investigator’s choice, after the 1.8 mg/kg arm (n = 62) was closed.2
Comparators in the second line were ramucirumab (Cyramza) plus paclitaxel, paclitaxel, or docetaxel. In the third or later line, the comparators were irinotecan, trifluridine/tipiracil (Lonsurf), or, in China only, apatinib.2 The dual primary end points were progression-free survival (PFS) by blinded independent central review in the second- or later-line population and OS in the third- or later-line population, with OS in the second- or later-line population serving as a key secondary end point.1 The trial is also being used to evaluate the Ventana SP455 assay for identifying CLDN18.2-positive tumors.1
Phase 3 Efficacy Findings
The trial met its OS primary end point in the third- or later-line population (median, 10.0 vs 5.0 months; HR, 0.47; 95% CI, 0.36-0.62; P < .000001). PFS was improved in the third-line or later and the ITT population by investigator assessment, but PFS in the second- or later-line population did not reach statistical significance (median, 4.2 vs 3.8 months; HR, 0.77; 95% CI, 0.62-0.96; P = .053).2
Among patients with measurable disease, the confirmed objective response rate was 23.3% vs 13.8%, and the median duration of response was 8.5 vs 6.8 months. OS benefit was observed in patients with CLDN18.2 expression of 75% or higher (HR, 0.59; 95% CI, 0.45-0.78) and of 25% to less than 75% (HR, 0.63; 95% CI, 0.42-0.94). In subgroup analyses whose confidence intervals were not adjusted for multiplicity, the OS HR was 0.88 (95% CI, 0.60-1.30) in patients treated in the second line and 1.08 (95% CI, 0.68-1.71) in those with GEJ cancer or esophageal adenocarcinoma.
Sonesitatug Vedotin Safety Profile
Grade 3 or higher adverse events (AEs) occurred in 52.9% of patients who received sonesitatug vedotin compared with 61.1% of those who received investigator’s choice, and AEs led to discontinuation in 5.0% vs 4.4%. Gastrointestinal AEs were more frequent with the ADC, including nausea (54.4% vs 26.6%), vomiting (41.0% vs 24.6%), and decreased appetite (43.3% vs 24.2%), whereas grade 3 or higher neutropenia was less frequent (10.3% vs 25.4%). Peripheral neuropathy occurred in 21.5% vs 14.3%, and treatment-related deaths occurred in 1.1% vs 0.8%.
Regulatory and Development Context
Sonesitatug vedotin holds orphan drug designation from the FDA and European Commission for gastric and GEJ cancers, and applications are under review in the European Union, China, and other countries.1 The agent is also being studied with capecitabine, with or without rilvegostomig (AZD2936), in the first-line phase 3 CLARITY-Gastric02 trial (NCT07431281).
“This priority review of our submission speaks to the significant potential of this medicine and accelerates the ability to bring forward a new targeted approach and alternative to traditional chemotherapy for thousands of patients in the US,” Susan Galbraith, MBBChir, PhD, executive vice president of oncology hematology research and development for AstraZeneca, stated in the news release.
REFERENCES
Sonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers. News release. AstraZeneca. November 19, 2026. Accessed November 19, 2026. https://tinyurl.com/v73wwxxh
Xu RH, Janjigian YY, Chen MH, et al. CLARITY-Gastric 01 (CG-01): a phase 3 study of sonesitatug vedotin (Sone-Ve) in second or later-line (2L+) advanced or metastatic Claudin 18.2 (CLDN18.2)-positive gastroesophageal carcinoma (GEC). Presented at: 2026 ESMO Congress; October 23-27, 2026; Madrid, Spain. Abstract LBA7.
Related to this article







